Zobrazeno 1 - 10
of 47
pro vyhledávání: '"E Castanon-Alvarez"'
Autor:
D. Cano Rafart, I. Vivas Pérez, M. Calvo Imirizaldu, G. Bastarrika Alemañ, E. Castanon Alvarez, J.P. de Torres Tajes, A. García-Baizán, A. Ezponda Casajús
Publikováno v:
Radiología (English Edition). 62:131-138
Objective To determine the incidence of immune-mediated adverse reactions with and without radiologic manifestations and to correlate them with the response to immunotherapy. Material and methods We retrospectively included 79 patients with stage IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e34bc24a1006b5ccd84eb36919975a8b
https://doi.org/10.1016/j.rxeng.2019.10.006
https://doi.org/10.1016/j.rxeng.2019.10.006
Autor:
M. Calvo Imirizaldu, I. Vivas Pérez, D. Cano Rafart, A. García-Baizán, G. Bastarrika Alemañ, E. Castanon Alvarez, J.P. de Torres Tajes, A. Ezponda Casajús
Publikováno v:
Radiología. 62:131-138
Resumen Objetivo Identificar la incidencia de reacciones adversas inmunomediadas (irAE, immune related adverse events), con y sin manifestaciones radiologicas, y correlacionarla con la respuesta al tratamiento inmunoterapico. Material y metodos Se re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69dc20515b53597b0e113436e8970c2c
https://doi.org/10.1016/j.rx.2019.06.004
https://doi.org/10.1016/j.rx.2019.06.004
Autor:
M. Imbimbo, A. Hollebecque, A. Italiano, M. McKean, T. Macarulla, E. Castanon Alvarez, B.A. Carneiro, R. Mager, V. Barnhart, E. Murtomaki, Y. He, Z.A. Cooper, E. Tu, A. Linke, C. Fan, D. Zhou, A. Boyer Chammard, C.L. Paturel, P.G. Fraenkel, J. Powderly
Publikováno v:
Immuno-Oncology and Technology. 16:100300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea6e17d6bbcde91b225af5f90a4c68b5
https://doi.org/10.1016/j.iotech.2022.100300
https://doi.org/10.1016/j.iotech.2022.100300
Autor:
Nancy Mueller, Benedito A. Carneiro, E. Castanon Alvarez, Johanna C. Bendell, Christophe Massard, Antoine Italiano, John D. Powderly, A. Gascó Hernández, T. Macarulla Mercade, M. Imbimbo
Publikováno v:
Annals of Oncology. 31:S728-S729
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b2a65a136905c85ce93ef30351e5ddb
https://doi.org/10.1016/j.annonc.2020.08.1193
https://doi.org/10.1016/j.annonc.2020.08.1193
Autor:
D Lebeherec, Claude Leclerc, Cecile Artaud, C Rossoni, B Verret, Stefan Michiels, E Castanon-Alvarez, Suzette Delaloge, M Lacroix-Tikri
Publikováno v:
Cancer Research. 78:P3-05
Background: Glycosylation is a post-translational modification generating complex carbohydrate O-glycans. Tn antigen, a N-acetyl-galactosamine-α-O-Ser/Thr residue that is the core glycosylated component of complex mucin-type O-glycans, is expressed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da5fdb9a324af36c62673e0f30cee7de
https://doi.org/10.1158/1538-7445.sabcs17-p3-05-14
https://doi.org/10.1158/1538-7445.sabcs17-p3-05-14
Autor:
L. Nebot, F. Longo, Julien Taieb, L. Gaba Garcia, P. Martin Romano, Benjamin Besse, H. Oliveres, Rocio Garcia-Carbonero, Antoine Hollebecque, Edouard Auclin, T. Sauri Nadal, M. Garcia De Herreros, J. Adeva Alfonso, E. Castanon Alvarez, Laura Mezquita, Christophe Massard, R. Vidal Tocino, Cristina Smolenschi, Y. El Dakdouki, P. Vuagnat
Publikováno v:
Annals of Oncology. 31:S1418
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcf1fad6350487eab115dc8634c9d6a5
https://doi.org/10.1016/j.annonc.2020.10.487
https://doi.org/10.1016/j.annonc.2020.10.487
Autor:
E. Castanon Alvarez, A. Sánchez, Manuel Rodriguez, Diego Salas, Jaime Espinós, Mariano Ponz-Sarvise, Ignacio Melero, M. Fernandez de Sanmamed, Arantxa González, J.M. López Picazo, Lizet Sánchez, Christian Vidal, L. Resano
Publikováno v:
Annals of Oncology. 31:S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f414ee80c398da457d1976d4bb75997a
https://doi.org/10.1016/j.annonc.2020.01.062
https://doi.org/10.1016/j.annonc.2020.01.062
Autor:
AI Idoate Grijalba, M.Á. García Del Barrio, E. Castanon Alvarez, I. Gil Bazo, B Sangro Gómez-Acebo
Publikováno v:
Eur J Hosp Pharm
Background ALK-inhibitors are indicated in adult patients with ALK-positive advanced NSCLC, with crizotinib being the first choice. Hepatotoxicity has been described for crizotinib and ceritinib. Purpose To describe a case of alectinib hepatic-tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23077f2406868cc47bbea8b84d28117
https://doi.org/10.1136/ejhpharm-2018-eahpconf.207
https://doi.org/10.1136/ejhpharm-2018-eahpconf.207
Autor:
L. Resano, P. Martin Romano, I. Melero, M.E. Rodriguez Ruiz, I. Baraibar Argota, A. Chopitea Ortega, E. Castanon Alvarez, Mariano Ponz-Sarvise, Miguel F. Sanmamed
First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2202de4160d169257125acc5b7411e
https://hdl.handle.net/10171/65316
https://hdl.handle.net/10171/65316
